Antivenom ViperaTAb - BTG

Drug Profile

Antivenom ViperaTAb - BTG

Alternative Names: Common adder antivenom ViperaTAb - Protherics; ViperaTAb

Latest Information Update: 18 Jan 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Protherics
  • Class Antivenins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Snake venom poisoning

Most Recent Events

  • 14 Jan 2010 Biovitrum has merged with Swedish Orphan to form Swedish Orphan Biovitrum
  • 04 Dec 2008 Protherics has been acquired and merged into BTG
  • 24 Jun 2003 ViperaTAb is available for licensing in the EU (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top